PEPTOKING
EN

China approves mazdutide, first dual glucagon and GLP-1 agonist for weight loss

Approval

China's National Medical Products Administration approved Innovent's mazdutide for chronic weight management in adults with a BMI of at least 28, or at least 24 with a weight-related condition. It is the first approved drug that activates both the glucagon and GLP-1 receptors. In the 48-week GLORY-1 trial in Chinese adults, weight fell by 12.0% on 4 mg and 14.8% on 6 mg versus 0.5% on placebo. Innovent develops mazdutide in China under a license from Eli Lilly.

Sources

  1. 01Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management(opens the source in a new tab) Innovent Biologics via PR Newswire
  2. 02With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs(opens the source in a new tab) Fierce Pharma

Peptides involved

  1. Approved elsewhereMazdutideGlucagon and GLP-1 receptor dual agonist (oxyntomodulin analog)34